Hepion Pharmaceuticals (NASDAQ:HEPA) (NASDAQ: HEPA) is a clinical‐stage biotechnology company dedicated to the discovery and development of novel therapeutics for the treatment of chronic liver diseases. The company’s primary focus is on non‐alcoholic steatohepatitis (NASH), a progressive liver disorder characterized by fat accumulation, inflammation and fibrosis. Hepion’s lead drug candidate, CRV431, is a proprietary cyclophilin inhibitor designed to target multiple pathways associated with liver inflammation and fibrosis, with the goal of halting disease progression and improving clinical outcomes for patients.
Founded in 2011, Hepion has leveraged its deep scientific expertise to build a pipeline that targets unmet needs in hepatology. In addition to CRV431, the company is advancing an oral formulation of CRV431 intended for combination therapy in viral hepatitis and hepatocellular carcinoma (HCC). Preclinical and early clinical studies have demonstrated the potential of these candidates to reduce liver scarring and support liver health. Hepion’s R&D efforts are supported by a modular platform that facilitates the rapid evaluation of drug combinations, enabling the company to adapt its approach as new data emerge.
Hepion Pharmaceuticals conducts its clinical trials primarily in North America and Europe, collaborating with leading academic and clinical research institutions to recruit patients and monitor outcomes. The company also explores strategic partnerships to expand its development capabilities and accelerate the global availability of its therapies. By engaging with regulatory authorities, Hepion aims to advance its most promising candidates through Phase II and III trials, with the objective of securing regulatory approval for the treatment of NASH and related indications.
The company’s leadership team is led by Chief Executive Officer Isaac Bell, who brings extensive experience in biopharmaceutical development, and Chief Medical Officer Dr. Vijay Khatri, an expert in liver disease therapeutics. Together with a board of directors composed of seasoned industry professionals, Hepion’s management leverages its collective expertise to navigate the complexities of drug development and deliver innovative treatments to patients with chronic liver conditions.
